摘要
目的:建立基于分级管理的静脉血栓栓塞症患者全程化抗凝管理模式(Integrated and hierarchical anticoagulation management mode for patients with venous thromboembolism,VTE-IHAM),并评价实践效果。方法:以文献计量学的方法建立VTE-IHAM。纳入2020年5月至2020年9月于南京大学医学院附属鼓楼医院住院的深静脉血栓(Deep venous thrombosis,DVT)患者,临床药师使用VTE-IHAM对患者进行抗凝治疗管理,并随访3个月,对抗凝质量和药师工作量进行分析。结果:建立了一套完整的VTE-IHAM,模式中包括分级管理和全程化管理两部分。共纳入98例DVT患者,与无差别监护管理模式相比,VTE-IHAM管理的患者在血栓栓塞和出血发生率方面无显著性差异;但是临床药师对每位患者的查房次数(5.0±2.6 vs 10.4±4.4,P<0.001)和总计管理时间(74.3±43.0 min vs 137.2±67.2 min,P<0.001)显著减少。结论:临床药师建立的VTE-IHAM,能够识别抗凝治疗高风险患者,规范工作流程和内容,提高了药师工作效率。
Objective:To establish an integrated and hierarchical anticoagulation management mode for patients with venous thromboembolism(VTE-IHAM),and evaluate its practical effects.Methods:The method of bibliometrics was used to establish VTE-IHAM.Patients with deep vein thrombosis(DVT)were enrolled,who were hospitalized in the Drum Tower Hospital Affiliated to Nanjing University Medical School from May 2020 to September 2020.Clinical pharmacists used VTE-IHAM to manage patients in anticoagulation therapy and followed up for three months.The quality of anticoagulation treatment and the workload of pharmacists were analyzed.Results:VTE-IHAM was established including a hierarchical management mode and an integrated management mode.A total of 98 DVT patients were enrolled.Compared with patients managed by the undifferentiated mode,patients managed by VTE-IHAM showed no significant difference in the incidence of thromboembolism and bleeding,while their number of ward rounds[(5.0±2.6)vs(10.4±4.4),P<0.001)]and total management time[(74.3±43.0)min vs(137.2±67.2)min,P<0.001]per patient by clinical pharmacists were significantly reduced.Conclusion:VTE-IHAM established by clinical pharmacists can identify high-risk patients in anticoagulant therapy,standardize the work process and content,and improve the work efficiency of pharmacists.
作者
戴梦飞
李舒悦
王宝彦
葛卫红
于锋
徐航
DAI Mengfei;LI Shuyue;WANG Baoyan;GE Weihong;YU Feng;XU Hang(Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China;School of Basic Medicine and Clinical Pharmacy,China Pharmaceutical University,Nanjing 210009,China)
出处
《药学与临床研究》
2022年第2期179-183,共5页
Pharmaceutical and Clinical Research
基金
江苏省药学会-Shire生物药学基金(S201606)
南京市医学科技发展资金资助(QRX17060)。
关键词
抗凝管理
新型口服抗凝药
注射类抗凝药
分级管理
全程化管理
Anticoagulation management
Novel oral anticoagulants
Injection anticoagulants
Hierarchical management
Integrated management